{"id":876270,"date":"2025-08-15T10:15:35","date_gmt":"2025-08-15T14:15:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-sarepta-therapeutics-inc-should-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-srpt\/"},"modified":"2025-08-15T10:15:35","modified_gmt":"2025-08-15T14:15:35","slug":"investors-in-sarepta-therapeutics-inc-should-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-srpt","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-sarepta-therapeutics-inc-should-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-srpt\/","title":{"rendered":"Investors in Sarepta Therapeutics, Inc. Should Contact Levi &amp; Korsinsky Before August 25, 2025 to Discuss Your Rights &#8211; SRPT"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">NEW YORK<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Aug. 15, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Levi &amp;\u00a0Korsinsky, LLP notifies investors in <b>Sarepta Therapeutics, Inc.<\/b> (&#8220;Sarepta&#8221; or the &#8220;Company&#8221;) (NASDAQ: SRPT) of a class action securities lawsuit.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg\" title=\"Levi &amp; Korsinsky, LLP (PRNewsfoto\/Levi &amp; Korsinsky, LLP)\" alt=\"Levi &amp; Korsinsky, LLP (PRNewsfoto\/Levi &amp; Korsinsky, LLP)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>\n        <b>CLASS DEFINITION: <\/b>The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by <span>alleged<\/span> securities <span>fraud<\/span> between <span class=\"xn-chron\">June 22, 2023<\/span> and <span class=\"xn-chron\">June 24, 2025<\/span>. Follow the link below to get more information and be contacted by a member of our team:<\/p>\n<p class=\"prntac\">\n        <a href=\"https:\/\/zlk.com\/pslra-1\/sarepta-lawsuit-submission-form?prid=161424&amp;wire=4\" rel=\"nofollow\">https:\/\/zlk.com\/pslra-1\/sarepta-lawsuit-submission-form?prid=161424&amp;wire=4<\/a>\n      <\/p>\n<p>\n        <b>SRPT<\/b>\u00a0investors may also contact <span class=\"xn-person\">Joseph E. Levi, Esq.<\/span> via email <a href=\"mailto:at\u00a0jlevi@levikorsinsky.com\u00a0or\" rel=\"nofollow\">at\u00a0jlevi@levikorsinsky.com\u00a0or<\/a> by telephone at (212) 363-7500.<\/p>\n<p>\n        <b>CASE DETAILS: <\/b>The filed complaint <span>alleges<\/span> that defendants made false statements and\/or concealed that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii) the severity of adverse events from ELEVIDYS treatment would cause the Company to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy&#8217;s present and expanded approvals; and (iv) as a result of the foregoing, defendants materially misled with, and\/or lacked a reasonable basis for, their positive statements.<\/p>\n<p>\n        <b>WHAT&#8217;S NEXT? <\/b>If you suffered a loss in Sarepta during the relevant time frame, you have until <b><span class=\"xn-chron\">August 25, 2025<\/span><\/b>\u00a0to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn&#8217;t require that you serve as a lead plaintiff.<\/p>\n<p>\n        <b>NO COST TO YOU: <\/b>If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. <b>There is no cost or obligation to participate.<\/b><\/p>\n<p>\n        <b>WHY LEVI &amp; KORSINSKY: <\/b>Over the past 20 years, the team at Levi &amp; Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi &amp; Korsinsky has ranked in ISS Securities Class Action Services&#8217; Top 50 Report as one of the top securities litigation firms in <span class=\"xn-location\">the United States<\/span>.<\/p>\n<p>\n        <b>CONTACT:<\/b><br \/>\n        <br \/>Levi &amp; Korsinsky, LLP <br \/><span class=\"xn-person\">Joseph E. Levi, Esq.<\/span><br \/><span class=\"xn-person\">Ed Korsinsky, Esq.<\/span><br \/>33 Whitehall Street, 17th Floor<br \/><span class=\"xn-location\">New York, NY<\/span> 10004<br \/><a href=\"mailto:jlevi@levikorsinsky.com\" rel=\"nofollow\">jlevi@levikorsinsky.com<\/a><br \/>Tel: (212) 363-7500<br \/>Fax: (212) 363-7171<br \/><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4489073-1&amp;h=1941164419&amp;u=https%3A%2F%2Fwww.zlk.com%2F&amp;a=www.zlk.com\" target=\"_blank\" rel=\"nofollow\">www.zlk.com<\/a><\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY52113&amp;sd=2025-08-15\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/investors-in-sarepta-therapeutics-inc-should-contact-levi--korsinsky-before-august-25-2025-to-discuss-your-rights--srpt-302530612.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/investors-in-sarepta-therapeutics-inc-should-contact-levi&#8211;korsinsky-before-august-25-2025-to-discuss-your-rights&#8211;srpt-302530612.html<\/a><\/p>\n<p>SOURCE  Levi &amp; Korsinsky, LLP<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY52113&amp;Transmission_Id=202508150915PR_NEWS_USPR_____NY52113&amp;DateId=20250815\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire NEW YORK , Aug. 15, 2025 \/PRNewswire\/ &#8212; Levi &amp;\u00a0Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. (&#8220;Sarepta&#8221; or the &#8220;Company&#8221;) (NASDAQ: SRPT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/sarepta-lawsuit-submission-form?prid=161424&amp;wire=4 SRPT\u00a0investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com\u00a0or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and\/or concealed that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-sarepta-therapeutics-inc-should-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-srpt\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Investors in Sarepta Therapeutics, Inc. Should Contact Levi &amp; Korsinsky Before August 25, 2025 to Discuss Your Rights &#8211; SRPT&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-876270","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Investors in Sarepta Therapeutics, Inc. Should Contact Levi &amp; Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-sarepta-therapeutics-inc-should-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-srpt\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Investors in Sarepta Therapeutics, Inc. Should Contact Levi &amp; Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK , Aug. 15, 2025 \/PRNewswire\/ &#8212; Levi &amp;\u00a0Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. (&#8220;Sarepta&#8221; or the &#8220;Company&#8221;) (NASDAQ: SRPT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/sarepta-lawsuit-submission-form?prid=161424&amp;wire=4 SRPT\u00a0investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com\u00a0or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and\/or concealed that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks &hellip; Continue reading &quot;Investors in Sarepta Therapeutics, Inc. Should Contact Levi &amp; Korsinsky Before August 25, 2025 to Discuss Your Rights &#8211; SRPT&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-sarepta-therapeutics-inc-should-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-srpt\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-15T14:15:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-in-sarepta-therapeutics-inc-should-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-srpt\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-in-sarepta-therapeutics-inc-should-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-srpt\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Investors in Sarepta Therapeutics, Inc. Should Contact Levi &amp; Korsinsky Before August 25, 2025 to Discuss Your Rights &#8211; SRPT\",\"datePublished\":\"2025-08-15T14:15:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-in-sarepta-therapeutics-inc-should-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-srpt\\\/\"},\"wordCount\":425,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-in-sarepta-therapeutics-inc-should-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-srpt\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280334\\\/Levi_and_Korsinsky_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-in-sarepta-therapeutics-inc-should-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-srpt\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-in-sarepta-therapeutics-inc-should-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-srpt\\\/\",\"name\":\"Investors in Sarepta Therapeutics, Inc. Should Contact Levi &amp; Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-in-sarepta-therapeutics-inc-should-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-srpt\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-in-sarepta-therapeutics-inc-should-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-srpt\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280334\\\/Levi_and_Korsinsky_Logo.jpg\",\"datePublished\":\"2025-08-15T14:15:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-in-sarepta-therapeutics-inc-should-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-srpt\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-in-sarepta-therapeutics-inc-should-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-srpt\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-in-sarepta-therapeutics-inc-should-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-srpt\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280334\\\/Levi_and_Korsinsky_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280334\\\/Levi_and_Korsinsky_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-in-sarepta-therapeutics-inc-should-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-srpt\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investors in Sarepta Therapeutics, Inc. Should Contact Levi &amp; Korsinsky Before August 25, 2025 to Discuss Your Rights &#8211; SRPT\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Investors in Sarepta Therapeutics, Inc. Should Contact Levi &amp; Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-sarepta-therapeutics-inc-should-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-srpt\/","og_locale":"en_US","og_type":"article","og_title":"Investors in Sarepta Therapeutics, Inc. Should Contact Levi &amp; Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT - Market Newsdesk","og_description":"PR Newswire NEW YORK , Aug. 15, 2025 \/PRNewswire\/ &#8212; Levi &amp;\u00a0Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. (&#8220;Sarepta&#8221; or the &#8220;Company&#8221;) (NASDAQ: SRPT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/sarepta-lawsuit-submission-form?prid=161424&amp;wire=4 SRPT\u00a0investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com\u00a0or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and\/or concealed that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks &hellip; Continue reading \"Investors in Sarepta Therapeutics, Inc. Should Contact Levi &amp; Korsinsky Before August 25, 2025 to Discuss Your Rights &#8211; SRPT\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-sarepta-therapeutics-inc-should-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-srpt\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-15T14:15:35+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-sarepta-therapeutics-inc-should-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-srpt\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-sarepta-therapeutics-inc-should-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-srpt\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Investors in Sarepta Therapeutics, Inc. Should Contact Levi &amp; Korsinsky Before August 25, 2025 to Discuss Your Rights &#8211; SRPT","datePublished":"2025-08-15T14:15:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-sarepta-therapeutics-inc-should-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-srpt\/"},"wordCount":425,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-sarepta-therapeutics-inc-should-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-srpt\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-sarepta-therapeutics-inc-should-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-srpt\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-sarepta-therapeutics-inc-should-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-srpt\/","name":"Investors in Sarepta Therapeutics, Inc. Should Contact Levi &amp; Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-sarepta-therapeutics-inc-should-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-srpt\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-sarepta-therapeutics-inc-should-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-srpt\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg","datePublished":"2025-08-15T14:15:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-sarepta-therapeutics-inc-should-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-srpt\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-sarepta-therapeutics-inc-should-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-srpt\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-sarepta-therapeutics-inc-should-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-srpt\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-in-sarepta-therapeutics-inc-should-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-srpt\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Investors in Sarepta Therapeutics, Inc. Should Contact Levi &amp; Korsinsky Before August 25, 2025 to Discuss Your Rights &#8211; SRPT"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/876270","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=876270"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/876270\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=876270"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=876270"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=876270"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}